RSLS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RSLS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Reshape Lifesciences has the Financial Strength Rank of 6.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.GuruFocus does not calculate Reshape Lifesciences's interest coverage with the available data. Reshape Lifesciences's debt to revenue ratio for the quarter that ended in Dec. 2023 was 0.03. As of today, Reshape Lifesciences's Altman Z-Score is -84.82.
For the Medical Devices subindustry, Reshape Lifesciences's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Reshape Lifesciences's Financial Strength distribution charts can be found below:
* The bar in red indicates where Reshape Lifesciences's Financial Strength falls into.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Reshape Lifesciences's Interest Expense for the months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the months ended in Dec. 2023 was $-1.90 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.15 Mil.
Reshape Lifesciences's Interest Coverage for the quarter that ended in Dec. 2023 is
GuruFocus does not calculate Reshape Lifesciences's interest coverage with the available data. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Reshape Lifesciences's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
Debt to Revenue Ratio | = | Total Debt (Q: Dec. 2023 ) | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (0.111 | + | 0.151) | / | 7.928 | |
= | 0.03 |
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Reshape Lifesciences has a Z-score of -84.82, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
Warning Sign:
Altman Z-score of -84.82 is in distress zone. This implies bankruptcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Reshape Lifesciences (NAS:RSLS) Financial Strength Explanation
The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.
Reshape Lifesciences has the Financial Strength Rank of 6.
Thank you for viewing the detailed overview of Reshape Lifesciences's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.
Thomas Stankovich | officer: Chief Financial Officer | 1001 CALLE AMANECER, SAN CLEMENTE CA 92673 |
Paul F. Hickey | director, officer: President and CEO | 2800 PATTON ROAD, ST. PAUL MN 55113 |
Barton P. Bandy | director | 1001 CALLE AMANECER, SAN CLEMENTE CA 92673 |
Mcdougal Lori Courtney | director | 2800 PATTON ROAD, ST. PAUL MN 55113 |
Arda Phd Minocherhomjee | director | C/O CHICAGO GROWTH PARTNERS, 303 W MADISON ST., SUITE 2500, CHICAGO IL 60606 |
Dan W Gladney | director | 2800 PATTON ROAD, ST. PAUL MN 55113 |
Steven Boyd | 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Armistice Capital, Llc | 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Gary Blackford | director | 7700 FRANCE AVENUE SOUTH, EDINA MN 55435 |
Robert J Macdonald | officer: Chief Retail Officer | C/O OBALON THERAPEUTICS INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008 |
Daina Schmidt | officer: Vice President of Marketing | C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, SAN DIEGO CA 92008 |
Gilbert H Kliman | 10 percent owner | C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022 |
Arnold L Oronsky | 10 percent owner | C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022 |
Khaled Nasr | 10 percent owner | 467 FIRST STREET, SUITE 201, LOS ALTOS X1 94022 |
Interwest Partners X Lp | 10 percent owner | C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022 |
From GuruFocus
By Marketwired • 06-28-2023
By Marketwired • 08-03-2023
By PRNewswire PRNewswire • 12-23-2022
By Marketwired • 09-22-2023
By Marketwired • 09-14-2023
By Value_Insider Value_Insider • 10-31-2022
By Tiesvg Tiesvg • 12-22-2022
By Value_Insider Value_Insider • 11-07-2022
By Stock market mentor Stock market mentor • 02-06-2023
By Marketwired • 08-07-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.